|
EP0368684B2
(en)
|
1988-11-11 |
2004-09-29 |
Medical Research Council |
Cloning immunoglobulin variable domain sequences.
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
AU675929B2
(en)
|
1992-02-06 |
1997-02-27 |
Curis, Inc. |
Biosynthetic binding protein for cancer marker
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
DE602004030811D1
(de)
|
2003-10-16 |
2011-02-10 |
Micromet Ag |
Multispezifische deimmunisierte cd3-bindende moleküle
|
|
JP5139800B2
(ja)
|
2004-06-03 |
2013-02-06 |
ノビミューン エスアー |
抗ｃｄ３抗体およびその使用方法
|
|
CA2606081C
(en)
*
|
2005-04-26 |
2013-09-17 |
Markus M. Heiss |
Combination of the application of antibodies for immunostimulation together with glucocorticoids
|
|
AU2006301492B2
(en)
|
2005-10-11 |
2011-06-09 |
Amgen Research (Munich) Gmbh |
Compositions comprising cross-species-specific antibodies and uses thereof
|
|
WO2008119565A2
(en)
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific binding domain
|
|
RS53008B2
(sr)
|
2007-04-03 |
2022-12-30 |
Amgen Res Munich Gmbh |
Interspecijski specifičan cd3-epsilon vezujući domen
|
|
AU2010297258A1
(en)
*
|
2009-09-18 |
2012-03-29 |
Amgen Research (Munich) Gmbh |
Dosage regimen for administering an EpCAMxCD3 bispecific antibody
|
|
CN103533943B
(zh)
*
|
2010-11-10 |
2018-02-13 |
安进研发（慕尼黑）股份有限公司 |
由cd3特异性结合结构域导致的不良作用的预防
|
|
DK2714733T3
(da)
|
2011-05-21 |
2019-05-06 |
Macrogenics Inc |
Cd3-bindende molekyler, der er i stand til at binde til human og ikke-human cd3
|
|
SG10201608307WA
(en)
|
2012-04-20 |
2016-11-29 |
Emergent Product Dev Seattle |
Cd3 binding polypeptides
|
|
EP2892924B1
(en)
|
2012-06-14 |
2020-11-25 |
Therapix Biosciences Ltd. |
Humanized antibodies to cluster of differentiation 3 (cd3)
|
|
EP2895203A4
(en)
|
2012-06-15 |
2016-09-28 |
Imaginab Inc |
ANTIGENBINDING CONSTRUCTS FOR CD3
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
EP2904016B1
(en)
*
|
2012-10-08 |
2018-11-14 |
Roche Glycart AG |
Fc-free antibodies comprising two fab-fragments and methods of use
|
|
CA2898100C
(en)
|
2013-01-14 |
2023-10-10 |
Xencor, Inc. |
Novel heterodimeric proteins
|
|
MX375359B
(es)
*
|
2013-02-26 |
2025-03-06 |
Roche Glycart Ag |
Moléculas biespecíficas de unión a antígeno activadoras de células t.
|
|
CA2902739C
(en)
|
2013-03-15 |
2022-11-22 |
Xencor, Inc. |
Heterodimeric proteins
|
|
WO2014191113A1
(en)
|
2013-05-28 |
2014-12-04 |
Numab Ag |
Novel antibodies
|
|
MX373245B
(es)
|
2013-07-05 |
2020-05-11 |
Genmab As |
Anticuerpos cd3 humanizados o quiméricos.
|
|
CN110627907B
(zh)
|
2013-11-04 |
2024-03-29 |
艾科诺斯科技股份有限公司 |
重靶向t细胞的异源二聚免疫球蛋白的产生
|
|
UA129760C2
(uk)
|
2013-12-17 |
2025-07-30 |
Дженентек, Інк. |
Анти-cd3 антитіло та спосіб його застосування
|
|
JP2017521998A
(ja)
|
2014-05-12 |
2017-08-10 |
ヌマブ アクチェンゲゼルシャフト |
新規多重特異性分子及びかかる多重特異性分子に基づく新規治療方法
|
|
CA2942453A1
(en)
|
2014-05-28 |
2015-12-03 |
F. Hoffmann-La Roche Ag |
Antibodies binding to human and cynomolgus cd3 epsilon
|
|
JP7020909B2
(ja)
|
2014-07-25 |
2022-02-16 |
シトムクス セラピューティクス，インコーポレイティド |
抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
|
|
EP2982693A1
(en)
|
2014-08-07 |
2016-02-10 |
Affimed Therapeutics AG |
CD3 binding domain
|
|
CR20170383A
(es)
|
2015-01-23 |
2017-11-22 |
Sanofi Sa |
Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
|
|
PL3988117T3
(pl)
|
2015-04-13 |
2025-03-10 |
Pfizer Inc. |
Przeciwciała terapeutyczne i ich zastosowania
|
|
EP3916018A1
(en)
|
2015-06-16 |
2021-12-01 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
SI3115376T1
(sl)
|
2015-07-10 |
2018-12-31 |
Merus N.V. |
Humana protitelesa, ki vežejo CD3
|
|
CN108368172B
(zh)
|
2015-07-15 |
2022-06-14 |
根马布股份公司 |
人源化或嵌合cd3抗体
|
|
EP3352760B1
(en)
|
2015-09-21 |
2026-03-11 |
Aptevo Research and Development LLC |
Cd3 binding polypeptides
|
|
LT3353212T
(lt)
|
2015-09-23 |
2021-12-27 |
Regeneron Pharmaceuticals, Inc. |
Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas
|
|
EP3356410B1
(en)
|
2015-10-02 |
2021-10-20 |
F. Hoffmann-La Roche AG |
Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
|
|
JP6949030B2
(ja)
*
|
2016-01-08 |
2021-10-13 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Ｐｄ−１軸結合アンタゴニスト及び抗ｃｅａ／抗ｃｄ３二重特異性抗体を用いたｃｅａ陽性がんの治療方法
|
|
CN116987189A
(zh)
|
2016-05-20 |
2023-11-03 |
哈普恩治疗公司 |
单链可变片段cd3结合蛋白质
|
|
CA3029209A1
(en)
|
2016-06-21 |
2017-12-28 |
Teneobio, Inc. |
Cd3 binding antibodies
|